Inclusion Criteria:

          1. Patients must have a histological or radiological diagnosis of untreated metastatic
             PDAC at screening with histology subsequently confirmed prior to randomization.

          2. Eligible histologic variants include adenocarcinoma or variants to include mucinous
             adenocarcinoma or adenosquamous carcinoma.

          3. Patients with a history of prior or concurrent second primary malignancy whose natural
             history or treatment does not have the potential to interfere with the safety or
             primary endpoint efficacy assessment of the pancreas cancer should generally be
             eligible for enrollment in clinical trials.

          4. Age ≥18 years.

          5. Patient must have a tumor lesion that is amenable to a core needle biopsy.

          6. Patients must be suitable for treatment with either mFFX and GA without
             contraindications to either regimen.

          7. Eastern Cooperative Group (ECOG) performance status 0-1. (Karnofsky ≥70%).

          8. Life expectancy of greater than 90 days, as judged by the investigator

          9. Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test and
             must agree to use adequate contraception (hormonal or barrier method of birth control;
             abstinence) prior to study entry and for the duration of study participation.

         10. Within 14 days of the proposed randomization date, patients must have normal organ and
             marrow function

        Exclusion Criteria:

          1. Patients who have received prior systemic treatment for PDAC, including treatment in
             the neoadjuvant or adjuvant setting. Prior surgery or palliative radiation is
             permitted.

          2. Patients with histology other than pancreatic ductal adenocarcinoma. Those with
             adenosquamous are allowed. Acinar tumors and colloid are excluded.

          3. Patients with one or more contraindications to tumor biopsy according to local
             institution's standard biopsy procedures.

          4. Patients with known brain metastases are excluded from participation in this clinical
             study.

          5. Uncontrolled inter-current illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, inability to stop anticoagulation medication for a biopsy, or psychiatric
             illness/social situations that would limit compliance with study requirements.

          6. Any other condition that would, in the Investigator's judgment, contraindicate the
             patient's participation in the clinical study due to safety concerns or compliance
             with clinical study procedures.

          7. Patients with a known germline mutation in BRCA, PALB2 or other homologous
             Recombination Repair Deficiency (HRD) genes.

          8. Patients who are pregnant or breastfeeding.

          9. Use (including 'recreational use') of any illicit drugs or other substance abuse
             (including alcohol) that could potentially interfere with adherence to study
             procedures or requirements. *Use of any illicit drugs or other substance abuse
             (including alcohol) are not screened in Canada using Toxicity testing. -